Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. KVUE
KVUE logo

KVUE Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
17.960
Open
17.950
VWAP
17.74
Vol
19.06M
Mkt Cap
33.83B
Low
17.605
Amount
338.09M
EV/EBITDA(TTM)
12.28
Total Shares
1.92B
EV
41.89B
EV/OCF(TTM)
19.07
P/S(TTM)
2.29
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
Show More

Events Timeline

(ET)
2026-02-26
16:30:00
Nasdaq Lags Despite Nvidia's Earnings Beat and Strong Guidance
select
2026-02-26
12:20:00
Texas Judge Dismisses Kenvue's Lawsuit Bid
select
link
2026-02-20 (ET)
2026-02-20
15:30:00
Kenvue Mentioned in M&A Rumor
select
2026-02-17 (ET)
2026-02-17
16:50:00
Kirk Perry: Q4 Revenue Reaches $3.78B for 2025
select

News

Benzinga
9.0
03-10Benzinga
FDA Approves Expanded Use of Wellcovorin for Cerebral Folate Deficiency
  • Drug Indication Expansion: The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in both adult and pediatric patients with confirmed FOLR1 gene variants, marking a significant advancement in the treatment of rare neurological diseases.
  • First Treatment Option: Wellcovorin becomes the first drug specifically indicated for cerebral folate deficiency, addressing common autism-like symptoms and severe developmental delays in patients, thereby offering new hope for improving their quality of life.
  • Scientific Basis for Approval: The FDA's approval was based on a systematic review of the literature, including patient-level information and mechanistic data, demonstrating the drug's efficacy and safety in clinical applications, which enhances confidence in its use.
  • Market Impact: Although GSK no longer manufactures Wellcovorin, the expanded approval allows generic versions to carry the new indication, which is expected to drive demand in the market and enhance treatment options for patients with cerebral folate deficiency.
Fool
8.0
03-10Fool
Dividend Kings: High-Quality Long-Term Investment Choices
  • Dividend Growth Potential: Genuine Parts plans to spin off its business, and despite a recent stock drop due to disappointing performance, its forward dividend yield of 3.7% and a 71-year history of dividend increases highlight its long-term investment appeal, especially with potential value unlock post-split.
  • Strategic Acquisition Opportunity: Kimberly-Clark is set to acquire Kenvue for $48.7 billion, expected to generate up to $2 billion in cost synergies, and shareholder support for the deal indicates reduced concerns over potential legal liabilities, which will help maintain its 54-year dividend growth record.
  • Target's Turnaround: Target's stock has surged over one-third in the past three months to $120 per share, and while there were initial doubts about its turnaround potential, an anticipated 12.2% earnings growth this year demonstrates its competitiveness in the retail market.
  • Dividend Yield Advantage: Target currently boasts a forward dividend yield of 3.9%, with an average annual increase of 7.7% over the past decade, and compared to Walmart's 43 times forward earnings, Target still presents a significant valuation discount, making it attractive for long-term investors.
NASDAQ.COM
8.5
03-10NASDAQ.COM
Genuine Parts Co. Split Plans May Unlock Value
  • Split Potential: Genuine Parts Co. is pursuing a split of its industrial distribution subsidiary, which could unlock significant value, especially given the valuation premium of industrial distributors like Fastenal, presenting a buying opportunity for investors before the split.
  • Stable Dividend Growth: The company has raised its dividend for 71 consecutive years, with an average annual growth rate of 5.3% over the past decade, and currently boasts a forward dividend yield of 3.7%, reflecting its strong dividend-paying capability.
  • Target's Turnaround: Target's stock has surged over one-third in the past three months to $120 per share, with earnings growth projected at 12.2% this year, indicating potential for further upside and a successful turnaround.
  • Kimberly-Clark Merger Impact: Kimberly-Clark's plan to acquire Kenvue for $48.7 billion is expected to create up to $2 billion in cost synergies, further solidifying its 54-year dividend growth track record, with a forward dividend yield of 3.5%.
Benzinga
8.5
03-10Benzinga
Emerging Consolidation Wave in U.S. Markets
  • Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
  • Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
  • Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
  • Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
CNBC
2.0
03-09CNBC
Analysis of Chewy's Undervalued Stock Reasons
  • Market Misunderstanding: Many investors perceive Chewy as a low-margin, highly competitive online pet retailer, overlooking its established habit-based consumer platform, which demonstrates greater resilience amid economic uncertainty.
  • Stability of Consumer Spending: Despite rising fuel costs and economic pressures, Chewy's products, such as dog food and cat litter, remain stable necessities, highlighting the difference between pet care and other discretionary consumer goods.
  • Financial Performance: Chewy is expected to grow revenues by over 8%, significantly higher than the S&P 500's average growth rate, yet it trades at a forward P/E of 16.5x, indicating a roughly 25% market discount, suggesting its stock is undervalued.
  • Technical Challenges: Despite strong fundamentals, Chewy's stock has fallen 23% year-to-date and is down over 78.5% from its all-time high, leading investors to adopt a wait-and-see approach ahead of its upcoming earnings report, contributing to a bearish market sentiment.
Fool
8.0
03-08Fool
The Investment Advantage of High-Quality Dividend Stocks
  • Dividend Return Comparison: A study by Hartford Funds and Ned Davis Research reveals that dividend stocks have achieved an annualized return of 9.2% from 1973 to 2024, significantly outperforming non-dividend payers at 4.31%, highlighting the long-term investment value of dividend stocks.
  • Microsoft's Dividend Power: Microsoft is set to pay over $27 billion in dividends over the next year, with a modest yield of 0.9%, yet its rapid growth in cloud computing and AI solutions provides robust cash flow support, ensuring substantial returns for shareholders.
  • ExxonMobil's Stability: ExxonMobil's annual dividend payout of $17.18 billion benefits from its integrated operating model, which helps maintain steady cash flow amid oil price fluctuations, especially with current geopolitical tensions driving prices higher, enhancing its outlook.
  • Apple's Dividends and Buybacks: Apple pays $15.27 billion in annual dividends and has repurchased $841 billion in stock since fiscal 2013, demonstrating strong cash flow and commitment to shareholder returns, while its pivot to subscription services is expected to further enhance future profitability.
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
Wall Street analysts forecast KVUE stock price to rise
1 Buy
7 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
17.00
Averages
18.86
High
23.00
Current: 0.000
sliders
Low
17.00
Averages
18.86
High
23.00
Barclays
Lauren Lieberman
Equal Weight
maintain
$18 -> $19
AI Analysis
2026-03-06
Reason
Barclays
Lauren Lieberman
Price Target
$18 -> $19
AI Analysis
2026-03-06
maintain
Equal Weight
Reason
Barclays analyst Lauren Lieberman raised the firm's price target on Kenvue to $19 from $18 and keeps an Equal Weight rating on the shares. The firm updated the company's model post the Q4 report.
Canaccord
Hold
maintain
$17 -> $18
2026-02-18
Reason
Canaccord
Price Target
$17 -> $18
2026-02-18
maintain
Hold
Reason
Canaccord raised the firm's price target on Kenvue to $18 from $17 and keeps a Hold rating on the shares. The firm said they reported a beat on the top and bottom line and saw all three business segments with year-over-year growth for the first time since 2Q23 due to some help from FX tailwinds.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KVUE
Unlock Now

Valuation Metrics

The current forward P/E ratio for Kenvue Inc (KVUE.N) is 15.99, compared to its 5-year average forward P/E of 18.14. For a more detailed relative valuation and DCF analysis to assess Kenvue Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.14
Current PE
15.99
Overvalued PE
20.24
Undervalued PE
16.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.81
Current EV/EBITDA
11.72
Overvalued EV/EBITDA
13.89
Undervalued EV/EBITDA
11.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.57
Current PS
2.16
Overvalued PS
2.89
Undervalued PS
2.26

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

5 stocks under $20 to t22rade everyday
Intellectia · 1186 candidates
Price: $1.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEWeekly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
KVUE logo
KVUE
Kenvue Inc
35.52B
HIMS logo
HIMS
Hims & Hers Health Inc
3.80B
SOFI logo
SOFI
SoFi Technologies Inc
26.11B
F logo
F
Ford Motor Co
55.19B
U logo
U
Unity Software Inc
9.27B
WULF logo
WULF
Terawulf Inc
6.71B
Texas coins
Intellectia · 4220 candidates
Region: US
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.51T
TIRX logo
TIRX
Tian Ruixiang Holdings Ltd
10.35M
AMZN logo
AMZN
Amazon.com Inc
2.26T
INTC logo
INTC
Intel Corp
252.65B
PLUG logo
PLUG
Plug Power Inc
2.89B
ADT logo
ADT
ADT Inc
6.62B
how about for swings?
Intellectia · 446 candidates
Market Cap: >= 5.00BSector: Consumer Cyclicals, Consumer Non-Cyclicals, Financials, Financial Technology (Fintech) & Infrastructure, Technology, Technology EquipmentMarket Cap Category: large, midList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ADT logo
ADT
ADT Inc
6.62B
NIO logo
NIO
NIO Inc
12.52B
BBD logo
BBD
Banco Bradesco SA
42.10B
IREN logo
IREN
IREN Ltd
13.88B
KVUE logo
KVUE
Kenvue Inc
34.74B
F logo
F
Ford Motor Co
54.99B
15 .00 to 20.00 for day trade
Intellectia · 198 candidates
Price: $15.00 - $20.00Price Change Pct: $-5.00 - $5.00Relative Vol: >= 1.50Weekly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
KVUE logo
KVUE
Kenvue Inc
34.36B
HBAN logo
HBAN
Huntington Bancshares Inc
38.67B
VALE logo
VALE
Vale SA
72.08B
INFY logo
INFY
Infosys Ltd
69.69B
HPQ logo
HPQ
HP Inc
18.47B
RKT logo
RKT
Rocket Companies Inc
54.50B
best stock today for day trading
Intellectia · 3393 candidates
Price: $1.00 - $200.00Volume: >= 50,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
RR logo
RR
Richtech Robotics Inc
1.12B
NVDA logo
NVDA
NVIDIA Corp
4.61T
INTC logo
INTC
Intel Corp
218.01B
NUWE logo
NUWE
Nuwellis Inc
6.31M
AAL logo
AAL
American Airlines Group Inc
9.10B
F logo
F
Ford Motor Co
55.04B
list the top 5 stocks by volume currently
Intellectia · 4692 candidates
Volume: >= 0List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
OPTT logo
OPTT
Ocean Power Technologies Inc
134.85M
BATL logo
BATL
Battalion Oil Corp
71.92M
INTC logo
INTC
Intel Corp
212.84B
SGN logo
SGN
Signing Day Sports Inc
3.06M
NVDA logo
NVDA
NVIDIA Corp
4.53T
GXAI logo
GXAI
Gaxos.ai Inc.
10.96M
list the top 5 stocks by volume
Intellectia · 4692 candidates
Volume: >= 0List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
OPTT logo
OPTT
Ocean Power Technologies Inc
134.85M
BATL logo
BATL
Battalion Oil Corp
71.92M
INTC logo
INTC
Intel Corp
212.84B
SGN logo
SGN
Signing Day Sports Inc
3.06M
NVDA logo
NVDA
NVIDIA Corp
4.53T
GXAI logo
GXAI
Gaxos.ai Inc.
10.96M
Can you tell me what to buy and why
Intellectia · 49 candidates
Price: $5.00 - $50.00Rsi Category: moderateList Exchange: XNYS, XNASMoving Average Relationship: PriceAboveMA20Is Index Component: GSPC, NDXMonthly Average Dollar Volume: >= 25,000,000
Ticker
Name
Market Cap$
top bottom
PFE logo
PFE
Pfizer Inc
147.20B
SMCI logo
SMCI
Super Micro Computer Inc
19.25B
CMCSA logo
CMCSA
Comcast Corp
105.27B
F logo
F
Ford Motor Co
54.87B
KVUE logo
KVUE
Kenvue Inc
33.30B
CMG logo
CMG
Chipotle Mexican Grill Inc
53.84B
best dividend kings
Intellectia · 24 candidates
Dividend Yield Ttm: >= 2Pe Ttm: <= 25
Ticker
Name
Market Cap$
top bottom
MO logo
MO
Altria Group Inc
102.53B
UVV logo
UVV
Universal Corp
1.37B
KVUE logo
KVUE
Kenvue Inc
33.30B
TGT logo
TGT
Target Corp
48.02B
BKH logo
BKH
Black Hills Corp
5.53B
KMB logo
KMB
Kimberly-Clark Corp
33.20B
best stocks in healthcare and energy
Intellectia · 20 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 1Rsi 14: 55 - 65Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
CTRA logo
CTRA
Coterra Energy Inc
20.37B
AMGN logo
AMGN
Amgen Inc
185.02B
WMB logo
WMB
Williams Companies Inc
77.16B
GILD logo
GILD
Gilead Sciences Inc
160.18B
TRGP logo
TRGP
Targa Resources Corp
40.80B
UNH logo
UNH
UnitedHealth Group Inc
315.01B

Whales Holding KVUE

L
LMR Partners LLP
Holding
KVUE
+15.67%
3M Return
T
Tudor Investment Corporation
Holding
KVUE
+7.46%
3M Return
M
Mondrian Investment Partners Limited
Holding
KVUE
+6.71%
3M Return
V
Vest Financial LLC
Holding
KVUE
+5.00%
3M Return
M
Magnetar Capital Partners, LP
Holding
KVUE
+4.72%
3M Return
B
Balyasny Asset Management L.P.
Holding
KVUE
+4.45%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Kenvue Inc (KVUE) stock price today?

The current price of KVUE is 17.65 USD — it has decreased -1.73

What is Kenvue Inc (KVUE)'s business?

Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

What is the price predicton of KVUE Stock?

Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is18.86 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Kenvue Inc (KVUE)'s revenue for the last quarter?

Kenvue Inc revenue for the last quarter amounts to 3.78B USD, increased 3.22

What is Kenvue Inc (KVUE)'s earnings per share (EPS) for the last quarter?

Kenvue Inc. EPS for the last quarter amounts to 0.17 USD, increased 13.33

How many employees does Kenvue Inc (KVUE). have?

Kenvue Inc (KVUE) has 21780 emplpoyees as of March 12 2026.

What is Kenvue Inc (KVUE) market cap?

Today KVUE has the market capitalization of 33.83B USD.